Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer
Trial · NCT02915523
Results by group37
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 37
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Phase 2: Progression Free Survival (PFS), as Determined by the Local Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) | Phase 2: Avelumab + Placebo | 1.51 | 95% Confidence Interval 1.45 to 2.50 | months | |
| Phase 2: Progression Free Survival (PFS), as Determined by the Local Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) | Phase 2: Avelumab + Entinostat | 1.64 | 95% Confidence Interval 1.41 to 2.69 | months | |
| Phase 1b: Number of Participants With at Least One Dose Limiting Toxicity (DLT) Adverse Event (AE) | Phase 1B: Avelumab + Entinostat (3 mg) | 0 | Participants | ||
| Phase 1b: Number of Participants With at Least One Dose Limiting Toxicity (DLT) Adverse Event (AE) | Phase 1B: Avelumab + Entinostat (5 mg) | 1 | Participants | ||
| Phase 1b: Recommended Phase 2 Dose (RP2D) | Phase 1B: Avelumab + Entinostat | 5 | mg | ||
| Phase 2: PFS, as Determined by the Local Investigator Using Immune Response RECIST (irRECIST) | Phase 2: Avelumab + Placebo | 2.10 | 95% Confidence Interval 1.45 to 2.79 | months | |
| Phase 2: PFS, as Determined by the Local Investigator Using Immune Response RECIST (irRECIST) | Phase 2: Avelumab + Entinostat | 1.77 | 95% Confidence Interval 1.45 to 2.69 | months | |
| Phase 2: Objective Response Rate (ORR), as Assessed Using RECIST 1.1 | Phase 2: Avelumab + Placebo | 4.88 | 95% Confidence Interval 0.60 to 16.53 | percentage of participants | |
| Phase 2: Objective Response Rate (ORR), as Assessed Using RECIST 1.1 | Phase 2: Avelumab + Entinostat | 5.88 | 95% Confidence Interval 1.94 to 13.20 | percentage of participants | |
| Phase 2: ORR, as Assessed Using irRECIST | Phase 2: Avelumab + Placebo | 2.44 | 95% Confidence Interval 0.06 to 12.86 | percentage of participants | |
| Phase 2: ORR, as Assessed Using irRECIST | Phase 2: Avelumab + Entinostat | 4.71 | 95% Confidence Interval 1.30 to 11.61 | percentage of participants | |
| Phase 2: Clinical Benefit Rate (CBR), as Assessed Using RECIST 1.1 | Phase 2: Avelumab + Placebo | 9.76 | 95% Confidence Interval 2.72 to 23.13 | percentage of participants | |
| Phase 2: Clinical Benefit Rate (CBR), as Assessed Using RECIST 1.1 | Phase 2: Avelumab + Entinostat | 11.76 | 95% Confidence Interval 5.79 to 20.57 | percentage of participants | |
| Phase 2: CBR, as Assessed Using irRECIST | Phase 2: Avelumab + Placebo | 9.76 | 95% Confidence Interval 2.72 to 23.13 | percentage of participants | |
| Phase 2: CBR, as Assessed Using irRECIST | Phase 2: Avelumab + Entinostat | 9.41 | 95% Confidence Interval 4.15 to 17.71 | percentage of participants | |
| Phase 2: Overall Survival | Phase 2: Avelumab + Placebo | 10.55 | 95% Confidence Interval 6.41 to 16.72 | months | |
| Phase 2: Overall Survival | Phase 2: Avelumab + Entinostat | 12.85 | 95% Confidence Interval 9.53 to 18.37 | months | |
| Phase 2: Duration of Response | Phase 2: Avelumab + Placebo | 6.83 | 95% Confidence Interval 4.14 to NA | months | |
| Phase 2: Duration of Response | Phase 2: Avelumab + Entinostat | 4.21 | 95% Confidence Interval 2.17 to 16.59 | months | |
| Phase 2: Time to Response | Phase 2: Avelumab + Placebo | 2.10 | 95% Confidence Interval 1.38 to 2.83 | months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02915523/results